Latest Strategic Review News

Pro-Pac Packaging is progressing a strategic review involving potential asset sales and liquidity support, with ASX trading suspension imminent pending financial disclosures.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

FBR Ltd reported a 57% revenue increase driven by property sales but posted a $29 million loss as it advances commercialization of its Hadrian X® robotic bricklayer and secures significant new funding.

AVADA Group Limited reported a revenue decline and a $9.7 million impairment on its New Zealand operations in FY25, while completing Phase 1 of its business transformation including ERP implementation and operational consolidation.

Linius Technologies reported a $5.31 million loss for FY25 as it shifts towards a sales-driven SaaS model, with new leadership and cost-cutting measures aiming to reshape its future.

Macarthur Minerals Limited reported a successful capital raise and key strategic partnerships at its 2025 AGM, positioning itself for future growth in iron ore production.

AVADA Group Limited reported a statutory net loss of $17.6 million for FY25, driven by impairments and challenging trading conditions, while completing a major business transformation aimed at future growth.

AVADA Group Limited reported a significant net loss of $17.6 million for FY25, driven by major impairments in New Zealand and New South Wales operations amid challenging market conditions. The company completed a strategic consolidation of its Australian businesses and appointed new senior management to steer operational transformation.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Aerometrex reported a slight dip in overall revenue for FY25 but achieved record growth in its MetroMap subscription business, driving a 19.8% rise in EBITDA. Strategic shifts and new leadership position the company for a leaner, more profitable future.

PEXA Group delivered a solid FY25 with 16% revenue growth and a 21% rise in EBITDA, while preparing for a UK platform launch backed by NatWest. Despite statutory losses from impairments, the company strengthened its balance sheet and outlined a confident FY26 outlook.

PEXA Group Ltd reported a robust FY25 with 16% revenue growth and a 21% rise in EBITDA, driven by national expansion and operational efficiencies. The company is advancing its UK platform launch backed by NatWest, while FY26 guidance signals continued growth and strategic focus on AI and resilience.